跳至主要内容
临床试验/ISRCTN41645723
ISRCTN41645723已完成3 期

Optimizing opioid assisted therapy : personalizing treatment using therapeutic drug monitoring and medication management

ational Rehabilitation Center0 个研究点目标入组 141 人开始时间: 2016年8月7日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
141

研究概览

简要总结

2019 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/30956839 protocol (added 05/08/2019) 2022 Other publications in https://pubmed.ncbi.nlm.nih.gov/35953563/ Association of buprenorphine elimination rate constant and opioid use (added 12/08/2022) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/33404141/ (added 12/08/2022)

研究设计

研究类型
Interventional

入排标准

性别
Male

入选标准

  • 1. Males and females aged 18- 64 years
  • 2. Diagnosed with current opioid use disorder (ICD-10)
  • 3. Current use of street heroin and/or pharmaceutical opioid
  • 4. Able to comprehend instructions and consent to the trial participation
  • 5. Voluntarily seeking treatment
  • 6. Able to be discharged to stable accommodation

排除标准

  • 1. Pregnant
  • 2. Patients with known hypersensitivity to naloxone or buprenorphine
  • 3. Hepatic Impairment (>3 times elevated liver function)
  • 4. Any prior suicidal attempt and current active suicide plan
  • 5. Involvement in current criminal justice proceedings
  • 6. Active uncontrolled severe mental illness or evidence of organic brain disease that is judged by clinical director to compromise patient safety
  • 7. Acute and severe respiratory illness
  • 8. Paralytic ileus
  • 9. Benzodiazepine use (in the past 28 days) in excess of 20 mg daily diazepam equivalent ,2

研究者

发起方
ational Rehabilitation Center

相似试验

Suboxone treatment and recovery trial | 临床试验